Oragenics News - OGEN

Company Name	Stock Ticker Symbol	Market	Type
Oragenics Inc	OGEN	AMEX	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	1.13	04:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
				1.13

more quote information »

Recent News

Date	Time	Source	Heading
4/01/2024	09:05	BW	Oragenics, Inc. Files 10K and Provides Company Update
3/18/2024	07:00	BW	Oragenics Appoints James Kelly MD, Chief Medical Officer, to..
3/06/2024	16:24	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
3/05/2024	07:45	BW	Oragenics, Inc. Prepares Drug for Phase II Clinical Trials..
3/01/2024	16:04	BW	Oragenics Announces Closing of Public Offering
2/29/2024	16:41	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2/28/2024	09:03	EDGAR2	Form 8-K - Current report
2/27/2024	21:25	BW	Oragenics Announces Pricing of Public Offering
2/27/2024	17:09	EDGAR2	Form FWP - Filing under Securities Act Rules 163/433 of free..
2/27/2024	17:04	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2/27/2024	16:33	BW	Oragenics Announces Proposed Public Offering
2/12/2024	20:06	EDGAR2	Form SC 13D - General statement of acquisition of beneficial..
2/12/2024	16:45	EDGAR2	Form 8-K - Current report
2/12/2024	16:41	BW	Oragenics, Inc. Announces Leadership Transition
2/07/2024	08:00	EDGAR2	Form 8-K - Current report
2/07/2024	08:00	BW	Oragenics, Inc. Announces Expiration of Its Investment..
2/05/2024	08:00	EDGAR2	Form 8-K - Current report
2/05/2024	08:00	BW	Oragenics, Inc. Preparing for Phase II Clinical Trials to..
1/23/2024	17:34	BW	Oragenics Announces Termination of At-The-Market Offering..
1/23/2024	17:18	EDGAR2	Form 8-K - Current report
1/22/2024	17:30	EDGAR2	Form 5 - Annual statement of changes in beneficial ownership..
1/16/2024	09:10	EDGAR2	Form 8-K - Current report
1/16/2024	09:08	EDGAR2	Form FWP - Filing under Securities Act Rules 163/433 of free..
1/16/2024	09:04	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
1/10/2024	16:37	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
1/02/2024	17:09	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/02/2024	09:22	EDGAR2	Form 8-K - Current report
1/02/2024	07:30	BW	Oragenics Completes Acquisition of Odyssey Health’s..
12/29/2023	07:30	EDGAR2	Form 8-K - Current report
12/15/2023	15:45	EDGAR2	Form 8-K - Current report
12/08/2023	16:00	EDGAR2	Form 8-K - Current report
12/01/2023	17:23	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/30/2023	17:50	EDGAR2	Form 144 - Report of proposed sale of securities
11/20/2023	15:45	EDGAR2	Form 8-K - Current report
11/16/2023	14:37	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
11/02/2023	07:00	EDGAR2	Form 8-K - Current report
11/02/2023	07:00	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
11/02/2023	07:00	BW	Oragenics Issues Update to Shareholders
10/30/2023	16:30	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
10/30/2023	16:00	EDGAR2	Form DEF 14A - Other definitive proxy statements
10/18/2023	08:30	BW	Oragenics Announces Appointment of Bruce Cassidy and John..
10/06/2023	16:33	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/06/2023	16:31	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/06/2023	16:28	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
10/06/2023	16:25	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
10/05/2023	17:29	EDGAR2	Form 8-K - Current report
10/05/2023	06:30	EDGAR2	Form 8-K - Current report
10/05/2023	06:30	BW	Oragenics to Acquire Odyssey Health’s Neurological Drug..
9/29/2023	16:00	EDGAR2	Form 8-K - Current report
9/29/2023	16:00	BW	Oragenics Enters into Agreement with Lantern Bioworks for..